July 31, 2024
… you lose some (Bloomberg)
Sometimes, though, even with a lot of phone calls, the message doesn’t get through. Such was the case with Bloomberg. Reporter Ike Swetlitz wrote a piece, “Unsafe Ozempic Knockoffs Are Flooding the Market,” that was chock full of the Chicken Little panic over compounded versions of GLP-1 drugs — and this after APC CEO Scott Brunner and Chief Advocacy Officer Tenille Davis spoke to Ike several times.
You can see why this is an uphill battle when a news organization like Bloomberg publishes stuff like, “They are made by so-called compounding pharmacies, an obscure corner of America’s pharmaceutical market that relies on a legal loophole to produce copies of treatments in short supply.”
We have since reached out to the editor to raise serious concerns with the “reporting” and to sternly correct the misrepresentations in the article. “In his piece, Ike has not reported a story so much as he has spun one,” wrote APC’s Scott Brunner. “From that headline insinuating all compounded drugs are unsafe, to at least one demonstrably incorrect characterization in the piece, to a complete failure of objectivity stating claims about compounded drugs by Novo and Lilly, the piece is sensational. It tells the story Ike wanted to tell, but it doesn’t quite tell the truth.”
